IL-17 (gene expression) as a new biological marker for diagnosing the gastric and colorectal cancer

Abstract

Background: Malignant gastrointestinal tumors such as esophageal, gastric, liver, colorectal, and pancreatic carcinomas are a major cause of cancer-related deaths worldwide proinflammatory cytokine interleukin-17 (IL-17) produced by Th17 cells, a T helper cell subset developed from an activated CD4+ T cell. IL-17 plays a potent role in T-cell mediated angiogenesis, promotes carcinogenesis and it has effects on immune resistance, proliferation and metastasis. This study was aimed to investicate the Serum IL-17 levels in Iraqi patients with GC and CRC. Materials and methods: peripheral Blood samples were collected from 30 Iraqi patient divided in to two groups 14women and 16 men with age rang 37-57 years, thay attended Gastroenterology and liver teaching hospital in Baghdad city and diagnosed with early detected (early onest) GC and CRC, and 30 healthy women and men were matched with patients as a control. IL-17 serum levels were measured using the highly sensitive Elisa kits (Human IL-17A Mini ABTS ELISA Development Kit , USA) Results:. Elisa assay demonstrated that IL-17 levels were highly expressed in GC and CRC patients, more especially in patients with early detected (early onset) disease.